Approaches to synthetic platelet analogs
Source abstract
Abstract
Platelet transfusion is routinely used for treating bleeding complications in patients with hematologic or oncologic clotting disorders, chemo/radiotherapy-induced myelosuppression, trauma and surgery. Currently, these transfusions mostly use allogeneic platelet concentrates, while products like lyophilized platelets, cold-stored platelets and infusible platelet membranes are under investigation. These natural platelet-based products pose considerable risks of contamination, resulting in short shelf-life (3-5 days). Recent advances in pathogen reduction technologies have increased shelf-life to ~7 days. Furthermore, natural platelets are short in supply and also cause several biological side effects. Hence, there is significant clinical interest in platelet-mimetic synthetic analogs that can allow long storage-life and minimum side effects. Accordingly, several designs have been studied which decorate synthetic particles with motifs that promote platelet-mimetic adhesion or aggregation. Recent refinement in this design involves combining the adhesion and aggregation functionalities on a single particle platform. Further refinement is being focused on constructing particles that also mimic natural platelet's shape, size and elasticity, to influence margination and wall-interaction. The optimum design of a synthetic platelet analog would require efficient integration of platelet's physico-mechanical properties and biological functionalities. We present a comprehensive review of these approaches and provide our opinion regarding the future directions of this research.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Platelet Disorders and Treatments · Periodontal Regeneration and Treatments · Blood properties and coagulation
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Current concepts in platelet transfusion10.4103/0973-6247.45257 ↗
2. Novel treatment modalities: new platelet preparations and substitutes10.1046/j.1365-2141.2001.03004.x ↗
3. Furie · 2003
4. 2012
5. The National blood collection and utilization survey report. 2012 Sept. Available from: URL: http://www.aabb.org/programs/biovigilance/nbcus/Pages/default.aspx.
6. Pathogen reduction of blood components10.1016/j.transci.2008.05.003 ↗
7. Pathogen-reduction systems for blood components: the current position and future trends10.1016/j.transci.2006.10.002 ↗
8. FDA approach to evaluation of pathogen reduction technology10.1046/j.1537-2995.2003.00584.x ↗
9. Impact of pathogen reduction technology and storage in platelet additive solutions on platelet function10.1111/j.1537-2995.2010.02914.x ↗
10. Pathogen reduction technology (Mirasol®) treated single-donor platelets resuspended in a mixture of autologous plasma and PAS10.1111/j.1423-0410.2009.01193.x ↗
11. Platelet refractoriness and alloimmunization
12. The reduction of HLA class I expression on platelets: a potential approach in the management of HLA-alloimmunized refractory patients10.1016/S0887-7963(99)80004-2 ↗
13. Immunomodulatory effects of allogeneic blood transfusions: clinical manifestations and mechanisms10.1111/j.1423-0410.1998.tb05437.x ↗
14. Transfusion-associated graft-versus-host disease10.1097/00062752-199704060-00015 ↗
15. Design and modification of nanoparticles for blood substitutes10.1007/4-431-27174-0_5 ↗
16. Alternatives to platelet transfusions in the management of platelet dysfunction or thrombocytopenia
17. Artificial blood: an update on current red cell and platelet substitutes
18. Novel platelet products, substitutes and alternatives10.1016/S1246-7820(01)00127-6 ↗
19. Platelets: structure, function, and their fundamental contribution to hemostasis and pathologic thrombosis
20. Human platelet size, shape, and related functions in health and disease10.1152/physrev.1982.62.1.185 ↗
21. The minimum energy of bending as a possible explanation of the bioconcave shape of the human red blood cell10.1016/S0022-5193(70)80032-7 ↗
22. Micro-scale dynamic simulation of erythrocyte-platelet interaction in blood flow10.1007/s10439-008-9478-z ↗
23. Quantification of the passive mechanical properties of the resting platelet10.1114/1.118 ↗
24. Stiffness of normal and pathological erythrocytes studied by means of atomic force microscopy10.1016/j.jbbm.2005.11.003 ↗
25. Measuring the viscoelastic properties of human platelets with the atomic force microscope10.1016/S0006-3495(96)79602-9 ↗
26. Flow behavior of erythrocytes. II. Particle motions in concentrated suspensions of ghost cells10.1016/0021-9797(79)90248-0 ↗
27. Dynamic and cellular interactions of nanoparticles in vascular-targeted drug delivery (review)10.3109/09687688.2010.499548 ↗
28. Red blood cell deformability influences platelets–vessel wall interaction in flowing blood10.1182/blood.V64.6.1228.1228 ↗
29. Micropipette aspiration of human platelets after exposure to aggregating agents10.1161/01.ATV.6.3.321 ↗
30. Platelet shape changes and adhesion under high shear flow10.1161/hq0202.104122 ↗
31. The vascular biology of the glycoprotein Ib-IX-V complex
32. Adhesion mechanisms in platelet function10.1161/01.RES.0000267878.97021.ab ↗
33. Platelet collagen receptors10.1055/s-0037-1616217 ↗
34. Platelet-collagen interaction: is GPVI the central receptor?10.1182/blood-2002-12-3882 ↗
35. The ligand binding site of the platelet integrin receptor GPIIb-IIIa is proximal to the second calcium binding domain of its alpha subunit10.1016/S0021-9258(19)39787-X ↗
36. Rolling properties of rGPIbalpha-conjugated phospholipid vesicles with different membrane flexibilities on vWf surface under flow conditions10.1016/S0006-291X(02)00934-8 ↗
37. Function of fibrinogen gamma-chain dodecapeptide-conjugated latex beads under flow10.1016/j.bbrc.2003.10.184 ↗
38. Prolonged hemostatic ability of polyethylene glycol-modified polymerized albumin particles carrying fibrinogen gamma-chain dodecapeptide10.1111/j.1537-2995.2007.01265.x ↗
39. Reconstitution of adhesive properties of human platelets in liposomes carrying both recombinant glycoproteins Ia/IIa and Ib alpha under flow conditions: specific synergy of receptor-ligand interactions10.1182/blood.V100.1.136 ↗
40. Deformability and adhesive force of artificial platelets measured by atomic force microscopy
41. Platelet interactions with liposomes carrying recombinant platelet membrane glycoproteins or fibrinogen: approach to platelet substitutes10.1081/BIO-100108550 ↗
42. Mimicking adhesive functionalities of blood platelets using ligand-decorated liposomes10.1021/bc300086d ↗
43. Relationship between the binding sites for von Willebrand factor, phospholipid, and human factor VIII C2 inhibitor alloantibodies within the factor VIII C2 domain10.1532/IJH97.06192 ↗
44. Promotion of human platelet adhesion and aggregation by a synthetic, triple-helical “mini-collagen”10.1016/S0021-9258(17)36732-7 ↗
45. Nanoparticles that display short collagen-related peptides. Potent stimulation of human platelet aggregation by triple helical motifs10.1021/bc070105s ↗
46. Thrombogenic collagen-mimetic peptides: self-assembly of triple helix-based fibrils driven by hydrophobic interactions10.1073/pnas.0800291105 ↗
47. Erythrocytes with covalently bound fibrinogen as a cellular replacement for the treatment of thrombocytopenia10.1111/j.1365-2362.1992.tb01943.x ↗
48. Thromboerythrocytes. In vitro studies of a potential autologous, semi-artificial alternative to platelet transfusions10.1172/JCI115619 ↗
49. Current and future cellular transfusion products10.1016/j.cll.2010.02.005 ↗
50. ProFibrix fibrocaps. 2012 Sept. Available from: URL: http://www.aabb.org/programs/biovigilance/nbcus/Pages/default.aspx.
51. Fibrinogen-coated albumin microcapsules reduce bleeding in severely thrombocytopenic rabbits10.1038/4795 ↗
52. A new hemostatic agent: thrombospheres shorten the bleeding time (BT) in thrombocytopenic rabbits
53. A novel approach to correcting the bleeding associated with thrombocytopenia
54. 2012
55. Intravenous hemostat: nanotechnology to halt bleeding10.1126/scitranslmed.3000397 ↗
56. RGD modified polymers: biomaterials for stimulated cell adhesion and beyond10.1016/S0142-9612(03)00343-0 ↗
57. Development of fibrinogen gamma-chain peptide-coated, adenosine diphosphate-encapsulated liposomes as a synthetic platelet substitute10.1111/j.1538-7836.2008.03269.x ↗
58. Hemostatic effects of fibrinogen gamma-chain dodecapeptide-conjugated polymerized albumin particles in vitro and in vivo10.1111/j.1537-2995.2005.00173.x ↗
59. Haemostatic effects of polymerized albumin particles carrying fibrinogen gamma-chain dodecapeptide as platelet substitutes in severely thrombocytopenic rabbits10.1111/j.1365-3148.2008.00860.x ↗
60. Hemostatic effects of phospholipid vesicles carrying fibrinogen gamma chain dodecapeptide in vitro and in vivo10.1021/bc050178g ↗
61. Design and synthesis of novel cyclic RGD-containing peptides as highly potent and selective integrin alpha IIb beta 3 antagonists10.1021/jm00027a001 ↗
62. Atrial fibrillation after bypass surgery: does the arrhythmia or the characteristics of the patients prolong hospital stay?10.1378/chest.113.6.1489 ↗
63. Peptide-decorated liposomes promote arrest and aggregation of activated platelets under flow on vascular injury relevant protein surfaces in vitro10.1021/bm300192t ↗
64. Role of platelets in atherothrombosis10.1038/nm1102-1227 ↗
65. Platelet interactions with vessel wall components during thrombogenesis10.1016/j.bcmd.2005.12.012 ↗
66. Contribution of distinct adhesive interactions to platelet aggregation in flowing blood10.1182/blood.V94.1.172.413k17_172_178 ↗
67. Effects of dried fraction from platelets on Ca clotting time of normal plasmas and plasma in thrombocytopenia and hemophilia
68. The preparation and clinical administration of lyophilized platelet material to children with acute leukemia and aplastic anemia10.1016/S0022-3476(56)80138-8 ↗
69. Hemostasis following the administration of lyophilized platelet material in secondary thrombocytopenia
70. Comparing effectiveness of fresh and lyophilized platelets in controlling irradiation hemorrhage in the rat10.3181/00379727-99-24481 ↗
71. Effectiveness of transfusions of fresh and lyophilized platelets in controlling bleeding due to thrombocytopenia10.1172/JCI103947 ↗
72. An application of lyophilization and scanning electron microscopy
73. Platelets fixed with paraformaldehyde: a new reagent for assay of von Willebrand Factor and platelet aggregating factor
74. Preservation of platelet receptors for platelet aggregating factor/von Willebrand factor by air drying, freezing, or lyophilization: new stable platelet preparations for von Willebrand factor assays10.1016/0049-3848(78)90148-2 ↗
75. Preservation of hemostatic and structural properties of rehydrated lyophilized platelets: potential for long-term storage of dried platelets for transfusion10.1073/pnas.92.2.397 ↗
76. Thrombus Formation with rehydrated, lyophilized platelets10.1080/1024533021000047954 ↗
77. Fibrinogen binding to rehydrated lyophilized platelet surface GPIIb-IIIa: normal clot formation and tPA lysis
78. Preclinical testing of lyophilized platelets as a product for transfusion medicine10.1016/0955-3886(95)97401-K ↗
79. The thrombocytopenic rabbit bleeding time model to evaluate the in vivo hemostatic efficacy of platelets and platelet substitutes10.1053/tm.1997.0110095 ↗
80. Hemostatic properties of human lyophilized platelets in a thrombocytopenic rabbit model and a simulated bleeding time device
81. Bleeding complications associated with cardiopulmonary bypass10.1182/blood.V76.9.1680.1680 ↗
82. Correction of the bleeding time with lyophilized platelet infusions in dogs on cardiopulmonary bypass10.1177/1076029607304746 ↗
83. Lyophilized platelets: nearing clinical trials
84. Lyophilized platelets for transfusion medicine
85. Hillyer · 2007
86. Trehalose lyophilized platelets for wound healing10.1111/j.1524-475X.2007.00207.x ↗
87. Lyophilization of human platelet and study of its aggregability
88. Lyophilized platelets: fifty years in the making10.1080/10731190600974962 ↗
89. Production and characterization of liquid-stored and lyophilized reconstituted human infusible platelet membranes10.1111/j.1751-553X.2011.01354.x ↗
90. Infusible platelet membranes retain partial functionality of the platelet GPIb/IX/V receptor complex10.1309/CCDV-3BEP-XXKP-BKDM ↗
91. Infusible platelet membranes improve hemostasis in thrombocytopenic blood: experimental studies under flow conditions10.1046/j.1537-2995.2000.40091074.x ↗
92. Frozen platelets and platelet substitutes in transfusion medicine10.1046/j.1537-2995.1997.37897424413.x ↗
93. A liposome based platelet substitute, the plateletsome, with hemostatic efficacy10.3109/10731199309117350 ↗
94. A platelet substitute-the plateletsome to be used in transfusion therapy
95. New strategy of platelet substitutes for enhancing platelet aggregation at high shear rates: cooperative effects of a mixed system of fibrinogen gamma-chain dodecapeptide- or glycoprotein Ibalpha-conjugated latex beads under flow conditions10.1007/s10047-006-0345-0 ↗
96. Potential role of size and hemodynamics in the efficacy of vascular-targeted spherical drug carriers10.1016/j.biomaterials.2009.11.007 ↗
97. Fujita H, Tsuji T, Tabata T, Takeoka S, Ikeda Y, Tanishita K. Motion of artificial platelet in the model arteriole. Proceedings of summer bioengineering conference. Key Biscayne, Florida. 2003: p. 29–30.
98. The effect of shape on the margination dynamics of non-neutrally buoyant particles in two-dimensional shear flows10.1016/j.jbiomech.2008.03.021 ↗
99. The effects of particle size, density and shape on margination of nanoparticles in microcirculation10.1088/0957-4484/22/11/115101 ↗
100. A theoretical model for the margination of particles within blood vessels10.1007/s10439-005-8976-5 ↗